PURE-EXO

What this means for you

This application is over — abandoned 21 Jan 2025. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.

Record

Serial number

90357314

Mark type

Stylized text

Filed

03 Dec 2020

Abandoned

21 Jan 2025

Attorney of record

Janice Housey

Goods and services

• Class 001 — Chemicals: Biological preparations, other than for medical or veterinary purposes; biological tissue cultures, other than for medical or veterinary purposes; biological preparation for use in cell cultures other than for medical or veterinary use; biological preparation for use in the manufacture of pharmaceuticals; chemical additives for use in the manufacture of pharmaceuticals; chemical additives for use in the manufacture of cosmetics; protein for use in the manufacture of cosmetics; proteins for the food industry; chemical reagents, other than for medical or veterinary purpose
• Class 005 — Pharmaceuticals: Pharmaceutical preparations for treating cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; chemico-pharmaceutical preparations for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; drug delivery agents for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; biological preparations comprising extracellular vesicles known as exosomes for therapeutic applications; extracellular vesicles for pharmaceutical purposes for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; biochemicial drug for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; nutraceutical preparations for therapeutic or medical purposes for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; chemical preparations for pharmaceutical purposes for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; chemical preparations for medical purposes for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; preparations of microorganisms for medical and veterinary use for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; reagents for use in medical genetic testing; diagnostic reagents for medical use; biological preparations for medical or veterinary purposes for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; biological reagents for clinical medical use
• Class 042 — Scientific and technological services: Biotechnology research; technological research in the field of cell biology; laboratory research in the field of cell biology; pharmaceutical drug development services; genetic testing for scientific research purposes; research in the field of chemistry; drug discovery services; medical research and development services; pharmaceutical research and development services; biopharmaceutical research and development services

Owner

• ILIAS Biologics Inc., Daejeon, KR

Prosecution history

• 05 Feb 2025 — ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
• 05 Feb 2025 — ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
• 23 Oct 2024 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
• 21 Oct 2024 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
• 21 Oct 2024 — TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
• 21 Oct 2024 — TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
• 21 Oct 2024 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
• 21 Oct 2024 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
• 18 Oct 2024 — NOTIFICATION OF FINAL REFUSAL EMAILED
• 18 Oct 2024 — FINAL REFUSAL E-MAILED
• 18 Oct 2024 — FINAL REFUSAL WRITTEN
• 24 Jun 2024 — TEAS/EMAIL CORRESPONDENCE ENTERED
• 24 Jun 2024 — CORRESPONDENCE RECEIVED IN LAW OFFICE
• 24 Jun 2024 — ASSIGNED TO LIE
• 26 May 2024 — TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED